Rheumatology Advanced Practice Providers (RhAPP 2025)
2025 Rheumatology Advanced Practice Providers | Sep 25-27 | Denver, CO
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
This document will be available on September 25 2025
Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients with Ulcerative Colitis: Results Through Week 24 from the Phase 3 ASTRO Study
This document will be available on September 25 2025
Guselkumab for Treatment of Juvenile Psoriatic Arthritis: Data Extrapolation from Studies in Adjacent Adult and Pediatric Populations
This document will be available on September 25 2025
Icotrokinra, a Novel Targeted Oral Peptide, in Patients with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis
This document will be available on September 25 2025
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
This document will be available on September 25 2025
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
This document will be available on September 25 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
